Cisplatin is retained in the cochlea indefinitely following chemotherapy

Cisplatin chemotherapy causes permanent hearing loss in 40–80% of treated patients. It is unclear whether the cochlea has unique sensitivity to cisplatin or is exposed to higher levels of the drug. Here we use inductively coupled plasma mass spectrometry (ICP-MS) to examine cisplatin pharmacokinetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Breglio, Andrew M., Rusheen, Aaron E., Shide, Eric D., Fernandez, Katharine A., Spielbauer, Katie K., McLachlin, Katherine M., Hall, Matthew D., Amable, Lauren, Cunningham, Lisa L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698400/
https://www.ncbi.nlm.nih.gov/pubmed/29162831
http://dx.doi.org/10.1038/s41467-017-01837-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698400/
https://www.ncbi.nlm.nih.gov/pubmed/29162831
http://dx.doi.org/10.1038/s41467-017-01837-1

Ejemplares similares